DSIP (Delta Sleep-Inducing Peptide)

DSIP is a small peptide first pulled from rabbit brain blood in the 1970s and named for an apparent ability to promote deep (“delta”) sleep. Decades later it is widely sold online as a sleep aid, but the human research behind it is thin, old, and inconsistent.

What it is

DSIP (delta sleep-inducing peptide) is a nine-amino-acid neuropeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Swiss researchers Schoenenberger and Monnier isolated it in 1974 from the cerebral venous blood of rabbits during an induced sleep state. It occurs naturally, and DSIP-like material has been reported in human breast milk, so it is not a designer drug but a native compound. Its mechanism remains poorly understood, and it is unusually unstable in the body, broken down quickly by a specific aminopeptidase-like enzyme (one in-vitro estimate puts its half-life near 15 minutes), which complicates any therapeutic use.

The claims

Vendors and peptide-forum write-ups promote DSIP mainly for better, deeper sleep and for treating insomnia. Secondary claims include reduced stress, blunted pain, easier opioid and alcohol withdrawal, and improved daytime recovery. Some marketing frames it as a “natural” sleep peptide free of next-day grogginess. These claims run well ahead of the published human evidence.

What the evidence actually shows

The clinical record is small and mostly from the 1980s. The largest controlled study, a placebo-controlled, double-blind report by Schneider-Helmert (European Neurology, 1987), gave DSIP to 14 middle-aged chronic insomniacs over seven nights and reported improved night sleep and daytime alertness. An earlier double-blind report by the same group (Experientia, 1981) tested just 6 chronic insomniacs and described longer, less interrupted sleep with no daytime sedation. A separate open (unblinded) trial of 7 severe insomniacs (Kaeser, European Neurology, 1984) reported that sleep “normalized” in all but one patient for several months. Small reports also described symptom relief in opioid- and alcohol-dependent patients.

Set against this, a 2006 review bluntly called DSIP’s status “a still unresolved riddle,” judging the hypothesis that DSIP acts as a sleep factor “extremely poorly documented and still weak,” and noting that some structural analogues — but not DSIP itself — showed activity in animals. The supportive trials are tiny (single digits to low teens), decades old, sometimes unblinded, short in duration, and have not been replicated by modern, adequately powered RCTs. Other studies have found no sleep effect at all. That places DSIP at the early, mixed end of human evidence, not the proven end.

Legal and regulatory status

DSIP is not approved by the FDA for any use. In the US it is sold as a “research chemical,” not a medicine or supplement. It had previously been treated as a Category 2 bulk substance (those raising significant safety concerns) for pharmacy compounding; in an updated 503A document dated April 15, 2026, the FDA removed DSIP (listed as “Emideltide”) from Category 2 and scheduled it for advisory review. The Pharmacy Compounding Advisory Committee is set to discuss it — as “Emideltide (also referred to as delta sleep-inducing peptide (DSIP))” — on July 24, 2026, as part of a July 23-24 meeting, to weigh inclusion on the 503A bulk drug substances list (Docket FDA-2025-N-6895). A scheduled review is not an approval, and none has been granted as of June 2026. DSIP is not named on the WADA Prohibited List, but unapproved peptides generally fall under category S0 (Non-Approved Substances) and are banned for athletes at all times; USADA has applied exactly this logic to other experimental peptides such as BPC-157.

Safety

There is no robust long-term or large-scale safety data in humans. The early trials reported few short-term side effects, but they were small and brief. Because DSIP is sold through unregulated channels, buyers also face uncertain purity, dosing, and contamination — problems that have caused failed drug tests and safety issues with peptides as a class. None of this is medical advice.

Bottom line

DSIP is a real, naturally occurring peptide with a handful of small, dated, and conflicting human sleep studies behind it. The signal is interesting but unproven, and modern high-quality trials simply do not exist. Evidence grade: Preliminary human.

Sources

• The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep — PubMed (PMID 7028502)
• Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia (Schneider-Helmert, European Neurology, 1987) — PubMed (PMID 3622582)
• A clinical trial with DSIP (Kaeser, European Neurology, 1984) — PubMed (PMID 6391926)
• Delta sleep-inducing peptide (DSIP): a still unresolved riddle (Kovalzon & Strekalova, 2006) — PubMed (PMID 16539679)
• Delta-sleep-inducing peptide — Wikipedia
• Pharmacy Compounding Advisory Committee; Notice of Meeting; Bulk Drug Substances Nominated for the 503A List — Federal Register (Docket FDA-2025-N-6895)
• July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — FDA
• S0 Non-Approved Substances — WADA Prohibited List
• BPC-157: Experimental Peptide Creates Risk for Athletes — USADA